Clinical Trial

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Name: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis — clinical trial record (NCT03773965)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: JUVE-X

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.

Trial Details

NCT Number	NCT03773965
Lead Sponsor	Eli Lilly and Company
Conditions	Juvenile Idiopathic Arthritis
Enrollment	190 participants
Start Date	2019-04-05
Primary Completion	2031-07 (estimated)
Study Completion	2031-07 (estimated)
Updated on ClinicalTrials.gov	2026-07-17